VANCOUVER, BC / ACCESS Newswire / August 22, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC:BNXTF) (FSE:BXT) reports two investor relations engagements. The Company has engaged Apaton Finance GmbH ("Apaton"), wholly owned by Mario Hose, of Ellernstr. 34, 30175 Hannover, Germany (email: office@apaton-finance.de; phone: +49 511 6768 731), pursuant to which Apaton will provide to the Company... Read More

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce two key milestones in the expansion and protection of its proprietary drug delivery platform targeting neurological autoimmune disorders. The Company has formally initiated the prioritized... Read More

VANCOUVER, BC / ACCESS Newswire / August 8, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC:BNXTF) (FSE:BXT), is pleased to announce today that it has closed the final tranche of its previously announced non‐brokered private placement (the " Offering ") of convertible debenture units (the " Debenture Units ") at a price of $0.60 per Debenture Unit, for gross proceeds of $241,200. The $241,200... Read More

VANCOUVER, BC / ACCESS Newswire / August 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE: BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce significant progress in its global patent portfolio. The Company has received formal communications from both the European Patent Office (EPO) and the Eurasian Patent Organization (EAPO),... Read More

VANCOUVER, BC / ACCESS Newswire / July 25, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT )(OTC:BNXTF) (FSE:BXT), is pleased to announce today that it has closed the first tranche of its previously announced non‐brokered private placement (the " Offering ") of convertible debenture units (the " Debenture Units ") at a price of $0.60 per Debenture Unit, for gross proceeds of $1,009,200. The $1,009,200... Read More

VANCOUVER, BC / ACCESS Newswire / July 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the successful formulation of a sublingual thin-film prototype for its lead clinical stage candidate, BNT23001, using the active pharmaceutical ingredient (API) cladribine. This proprietary... Read More

VANCOUVER, BC / ACCESS Newswire / July 11, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK: BNXTF ) (FSE: BXT ), is pleased to announce its intention to complete a non‐brokered private placement (the " Offering ") of convertible debenture units (the " Debenture Units ") at a price of $0.60 per Debenture Unit, for gross proceeds of up to $1,200,000. Each Debenture Unit consists of: (i) $0.60... Read More

VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, today announces the advancement of a potential breakthrough targeted chemotherapy delivery platform designed to address a critical unmet need in precision oncology by localizing toxic... Read More

VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC:XPHYF) (FSE:4XT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the receipt of the active pharmaceutical ingredient (API) for its lead product candidate, BNT23001. This proprietary sublingual thin-film formulation of cladribine is being developed for the... Read More

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), is pleased to announce that effective immediately, the British Columbia Securities Commission has revoked the temporary management cease trade order (" MCTO ") it had previously granted to the Company on May 1, 2025 under National Policy 12-203 Management Cease Trade Orders , as the... Read More

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC:BNXTF) (FSE:BXT), is pleased to announce the launch of a feasibility study for the development of an oral dissolvable film (ODF) formulation of Semaglutide, a GLP-1 receptor agonist currently marketed globally under the brand names Ozempic®, Rybelsus®, and Wegovy®. This initiative marks a significant step in... Read More

VANCOUVER, BC / ACCESS Newswire / June 12, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:4XT), announces that, further to its news release dated May 1, 2025 (the " Default Announcement "), the Company's principal regulator, the British Columbia Securities Commission (the " BCSC ") granted a management cease trade order (the " MCTO ") on May 1, 2025, under National Policy 12-203... Read More

VANCOUVER, BC / ACCESS Newswire / May 29, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), announces that, further to its news release dated May 1, 2025 (the " Default Announcement "), the Company's principal regulator, the British Columbia Securities Commission (the " BCSC ") granted a management cease trade order (the " MCTO ") on May 1, 2025, under National Policy 12-203... Read More

VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the examining division of the European Patent Office ("EPO") has provided formal notice of the EPO's intention to grant BioNxt its core patent without significant changes. The Company's core... Read More

VANCOUVER, BC / ACCESS Newswire / May 15, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:XPHYF) (FSE:4XT), announces that, further to its news release dated May 1, 2025 (the " Default Announcement "), the Company's principal regulator, the British Columbia Securities Commission (the " BCSC ") granted a management cease trade order (the " MCTO ") on May 1, 2025, under National Policy 12-203... Read More

VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is pleased to announce the integration of its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG (Gen-Plus) Contract Research and Development Organization (CRDO) in Munich, Germany. The... Read More

VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the Company's core patent claims, namely: novelty, inventive step, and... Read More

VANCOUVER, BC / ACCESS Newswire / May 1, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC:BNXTF) (FSE:BXT), announces that its annual financial statements for the year ended December 31, 2024, the related management discussion and analysis, and certifications of the Chief Executive Officer (the " CEO ") and the Chief Financial Officer (the " CFO ") (collectively, the " Annual Filings "), were not... Read More

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of... Read More

VANCOUVER, BC / ACCESS Newswire / March 14, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC: BNXTF ) (FSE:BXT), is pleased to announce that, further to its news release of February 28, 2025, it has closed the final tranche of its previously announced non‐brokered private placement (the " Offering ") of convertible debenture units (" Debenture Units ") for gross proceeds of $900,000. The Company... Read More

VANCOUVER, BC / ACCESS Newswire / February 28, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:4XT), is pleased to announce today that it has closed the first tranche of its previously announced non‐brokered private placement (the " Offering ") of convertible debenture units (" Debenture Units ") for gross proceeds of $1,600,000. Each Debenture Unit consists of: (i) $0.50... Read More

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:4XT), announces a non-brokered private placement of debenture units (the " Debenture Units ") with each unit consisting of $0.50 in principal amount of debenture bearing interest at a rate of 8.0% per annum for a period of two years following the closing date (the " Debenture "),... Read More

VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:4XT) reports a clarification to its news release dated January 31, 2025, at the request of the Canadian Investment Regulatory Organization ("CIRO"). The Company engaged Apaton Finance GmbH ("Apaton"), wholly owned by Mario Hose, of Ellernstr. 34, 30175 Hannover, Germany (email:... Read More

VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report on several major milestones for the next 90 days, including the registration of national-level patents, the completion of a human bioequivalence study for its lead Multiple Sclerosis (MS)... Read More

VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in... Read More

VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the expansion of its intellectual property portfolio with the filing of new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. Building upon... Read More

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork... Read More

VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration... Read More

VANCOUVER, BC / ACCESSWIRE / November 25, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT) is pleased to announce the expansion of its next-generation product pipeline. This includes proprietary Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet) drug delivery systems targeting autoimmune diseases such as Multiple sclerosis ("MS"), Myasthenia... Read More

VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT) is pleased to announce that it has initiated the nationalization process for the filing of a family of patents for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. The patents are 100% owned by BioNxt. Subject to the international... Read More

VANCOUVER, BC / ACCESSWIRE / October 7, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT) is pleased to announce that Terry Lynch has joined the BioNxt team as a capital markets advisor. Mr. Lynch brings decades of start-up and emerging growth capital markets experience in the resource and bioscience sectors, including finance and M&A, as well as an extensive and influential... Read More

VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to provide an update on its flagship sublingual Cladribine drug formulation program for the treatment of Multiple Sclerosis ("MS"), broad sublingual patent application for the use of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, and investor... Read More

VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC PINK:BNXTF) (FSE:BXT) is pleased to report that the European Patent Office ("EPO") has issued a positive international examination report for the Company's comprehensive patent application for sublingual delivery of anticancer drug for the treatment of autoimmune neurodegenerative diseases. The Company... Read More

VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group. Further to the Master Service Agreement and Cladribine... Read More

VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has signed a statement of work ("SOW") with a German-based international contract research, development, and manufacturing organization (the "CRDMO"). The SOW is focused on the Company's flagship Cladribine oral dissolvable film ("ODF") development program. The SOW... Read More

VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has signed a master services agreement ("MSA") with a German-based international contract research, development, and manufacturing organization (the "CRDMO"). The MSA will serve as the foundation for BioNxt's future product development, particularly its pipeline of... Read More

VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce that, further to its news releases dated April 25, 2024, and May 10, 2024, the Company has closed the second tranche of its non-brokered private placement in the amount of 1,000,000 common shares in the capital of the Company (each, a " Common Share ") at a price of... Read More

VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce that, further to its news releases dated April 25, 2024, and May 10, 2024, the Company has closed the second tranche of its non-brokered private placement in the amount of 1,000,000 common shares in the capital of the Company (each, a " Common Share ") at a price of... Read More

VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC:BNXTF) (FSE:BXT) is pleased to announce that its Cladribine program is advancing to human comparative bioavailability studies in Europe. The Company is reviewing proposals from several contract research organizations to carry out the studies in accordance with EU medical regulatory guidelines. The recent... Read More

VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that based on the recent success of its toxicity and comparative pharmacokinetic ("PK") studies the Company is advancing towards human comparative bioavailability studies on an expedited basis. The next steps in the development and commercialization process include... Read More

VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary Cladribine product for the treatment of Multiple Sclerosis ("MS") has been completed and results received by the Company. The animal PK study results are highly... Read More

VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary Cladribine product for the treatment of Multiple Sclerosis ("MS") has been completed. Results will be reported by the Company when available. The PK study closely... Read More

VANCOUVER, BC / ACCESSWIRE / February 16, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to announce that it has finalized and executed a settlement agreement (the " Settlement Agreement ") with a creditor of the Company (the " Creditor ") to settle an aggregate of $282,415 in debt (the " Debt ") accrued through a combination of equipment sold and services provided... Read More

VANCOUVER, BC / ACCESSWIRE / February 7, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that the toxicity study for its oral dissolvable film ("ODF") based proprietary Cladribine product for the treatment of Multiple Sclerosis ("MS") has been completed and results received by the Company. The study was unanimously successful with positive results in all... Read More

VANCOUVER, BC / ACCESSWIRE / January 29, 2024 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT / OTCQB: BNXTF / FSE:4XT) is pleased to announce that, further to its news releases dated December 21, 2023, December 28, 2023 and January 4, 2024, the Company has closed the final tranche of its non-brokered private placement in the amount of 720,000 units of the Company (the " Units ") at a price of $0.40 per... Read More

VANCOUVER, BC / ACCESSWIRE / December 21, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to announce that the toxicity study for its proprietary oral dissolvable film ("ODF") based Cladribine product for the treatment of Multiple Sclerosis ("MS"), first announced November 20, 2023, is now complete. The study was carried out by a European contract research... Read More

VANCOUVER, BC / ACCESSWIRE / December 12, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:NXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to announce that it has received delivery of state-of-the-art coating and cutting equipment necessary for the buildout of commercial manufacturing capacity at its Vektor Pharma TF GmbH ("Vektor") facility in Baden-Württemberg, Germany. The German-designed and manufactured coating... Read More

VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) announces that, further to its news release dated November 24, 2023, it has settled an aggregate of $2,581,096 in convertible debentures and interest (the " Debt ") owed to an arm's length creditor of the Company (the " Creditor "). In settlement of the Debt the Company issued the Creditor:... Read More

VANCOUVER, BC / ACCESSWIRE / November 24, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) announces that it will be entering into a debenture and interest settlement agreement with an arm's length creditor of the Company (the " Creditor ") to settle an aggregate of $2,581,096 in convertible debentures and interest (the " Debt "). In settlement of the Debt the Company will issue... Read More

VANCOUVER, BC / ACCESSWIRE / November 20, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to provide further details on its clinical and commercialization strategy for its recently announced 100% Cladribine IP acquisition and related clinical programs. BioNxt has accelerated development of a proprietary oral dissolvable film ("ODF") based Cladribine product for the... Read More

VANCOUVER, BC / ACCESSWIRE / November 15, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to provide further development details on its recently announced 100% Cladribine IP acquisition and related development program. BioNxt has commenced the development and commercialization of a proprietary oral dissolvable film ("ODF") based Cladribine product for the treatment... Read More

VANCOUVER, BC / ACCESSWIRE / November 13, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has signed a definitive agreement (the "Agreement") with a German-based pharmaceutical developer for the acquisition of 100% of the intellectual property rights and joint development of an oral dissolvable ("ODF") drug reformulation using the active... Read More

VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / 6. November 2023 / BioNxt Solutions Inc. („ BioNxt" oder das „Unternehmen ") (CSE: BNXT)(OTC: XPHYF)(FWB: 4XT) freut sich, über einen erfolgreichen CPHI-Pharmakongress in Barcelona (Spanien) zu berichten, an dem das europäische Team von BioNxt vor kurzem teilgenommen hat („CPHI"). CPHI ist der größte Kongress der Pharmaindustrie weltweit mit mehr als 45.000 Teilnehmern und 1.500... Read More

VANCOUVER, BC / ACCESSWIRE / November 6, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTFF) (FSE:BXT) is pleased to report on a successful CPHI pharma conference in Barcelona, Spain, recently attended by BioNxt's European team ("CPHI"). CPHI is the largest pharma industry conference in the world with over 45,000 attendees and 1,500 exhibitors from over 150 countries. CPHI provides an... Read More

VANCOUVER, BC / ACCESSWIRE / October 27, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce that, further to its news releases dated August 4, August 28, and September 29, 2023, the Company has closed the third and final tranche of its non-brokered private placement in the amount of 2,050,000 common shares in the capital of the Company (the " Shares ") at a... Read More

VANCOUVER, BC / ACCESSWIRE / October 3, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT), announces that Per Thoresen and Peter Damouni have resigned as directors of the Company. The Company would like to thank Mr. Thoresen and Mr. Damouni for their contributions to the Company. The Company is pleased to also announce that Joseph Meagher, the Chief Financial Officer of the... Read More

VANCOUVER, BC / ACCESSWIRE / September 28, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce that, further to its news releases dated August 4 and August 28, 2023, the Company has closed the second tranche of its non-brokered private placement in the amount of 2,500,000 common shares in the capital of the Company (the " Shares ") at a price of $0.265 per... Read More

VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to announce a non-brokered private placement of up to 15,000,000 common shares of the Company (the " Common Shares ") at a price of $0.265 per Common Share for gross proceeds of up to $3,975,000 (the " Offering "). The Company intends to use the net proceeds from the Offering for... Read More

VANCOUVER, BC / ACCESSWIRE / August 2, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has signed a non-binding letter of intent with two European-based parties (the "Parties") to acquire 100% of the intellectual property rights, which are currently co-owned by BioNxt, and to co-develop an oral dissolvable film ("ODF") drug reformulation... Read More

VANCOUVER, BC / ACCESSWIRE / May 15, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has received government approval for to proceed with its comparative drug absorption study for the Company's transdermal ("TDS") Rotigotine patch for the treatment of Parkinson's disease. The study is expected to commence in four to six weeks. Further to BioNxt's... Read More

VANCOUVER, BC / ACCESSWIRE / May 9, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to announce that it has successfully completed a human pilot study for a leading European-based generic drug company. BioNxt successfully developed the oral dissolvable ("ODF") narcotics product and managed the comparative bioavailability study. "BioNxt is actively building a... Read More

VANCOUVER, BC / ACCESSWIRE / April 24, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to announce that it has signed and received payment for a development and manufacturing contract (the "Contract") with an international pharmaceutical company (the "Client"). The Contract is focused on the development of an oral dissolvable ("ODF") pharmaceutical product based on... Read More

VANCOUVER, BC / ACCESSWIRE / April 17, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to announce that it has purchased state-of-the-art coating and cutting equipment to build out its commercial manufacturing capacity at its Vektor Pharma TF GmbH ("Vektor") facility in Baden-Württemberg, Germany. The equipment is CE certified and capable of manufacturing the... Read More

VANCOUVER, BC / ACCESSWIRE / April 14, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to provide an update on its enteric coating and drug delivery program for solid oral drug dosage forms. BioNxt's contract research partner has completed the production of prototype active pharmaceutical ingredient ("API") coated tablets using the Company's recently acquired... Read More

VANCOVER, BC / ACCESSWIRE / April 3, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) announces that, further to its news release of March 27, 2023, the Company has closed its non-brokered private placement of units previously announced on March 10, 2023. No additional tranches of the non-brokered private placement were completed. The securities issued pursuant to the Offering... Read More

VANCOUVER, BC / ACCESSWIRE / March 27, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), is pleased to announce that further to its news release of March 10, 2023, it has closed the first tranche of its private placement (the " Offering "). The Company issued 4,050,000 units (the " Units ") at $0.50 per Unit for total gross proceeds of $2,025,000. Each Unit consists of one common... Read More

VANCOUVER, BC / ACCESSWIRE / March 10, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(FSE:4XT) is pleased to announce a non-brokered private placement of up to 5,000,000 units of the Company (the " Units ") at a price of $0.50 per Unit for gross proceeds of up to $2,500,000 (the " Offering "). Each Unit will be comprised of one common share in the capital of the Company (a " Share ") and one-half of... Read More

VANCOUVER, BC / ACCESSWIRE / March 7, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has signed a definitive technology transfer and patent assignment agreement (the "Agreement") to acquire certain technology and intellectual property assets and rights related to a novel solid oral drug dosage form coating and delivery technology (the... Read More

VANCOUVER, BC / ACCESSWIRE / March 2, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:4XT), is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (" Canaccord ") to assist in the exercise of up to 5,000,000 common share purchase warrants (the " Warrants ") issued by the Company on August 2, 2022, August 30, 2022, and September 2, 2022, on a... Read More

VANCOUVER, BC / ACCESSWIRE / March 1, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) is pleased to report that it has executed an agreement to carry out its comparative drug absorption study for the Company's transdermal ("TDS") Rotigotine patch for the treatment of Parkinson's disease. BioNxt has also commenced the manufacture of clinical samples for use in the study which is... Read More

VANCOUVER, BC / ACCESSWIRE / February 13, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTC:BNXTF) (FSE:BXT) is pleased to report an update on its commercialization plan for its transdermal Rotigotine patch for the treatment of Parkinson's disease ("PD"). The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH... Read More

VANCOUVER, BC / ACCESSWIRE / December 12, 2022 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) is pleased to report that it has signed a non-binding term sheet (the "Term Sheet") for the acquisition of certain intellectual property assets and rights related to a novel solid oral drug dosage form coating delivery technology (the "Technology"). The Term Sheet sets out a number of terms... Read More

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 7, 2022 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT), is pleased to announce today that it has closed its non-brokered private placement of convertible debentures (the " Offering "), pursuant to which it raised the principal amount of $2,808,000 (the... Read More

VANCOUVER, BC / ACCESSWIRE / December 5, 2022 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT), in connection with the Company's news release dated November 29, 2022 regarding a non-brokered private placement of debentures (the " Offering "), is pleased to announce that it is increasing the size of the Offering to $2,808,000 from $2,600,000. The Company further clarifies the terms of... Read More

VANCOUVER, BC / ACCESSWIRE / November 29, 2022 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT), an international drug formulation and diagnostics company, is pleased to announce a non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of up to $2,600,000 (the "Offering"). Each Unit is convertible into 1,923 common... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) ( FSE:4XT) ("XPhyto" or the "Company") is pleased to report the results of its Rotigotine transdermal ("TDS") patch human skin cadaver study and dissolution data. The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Further to the Company's product update on October 11, 2022,... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product development report on its Rotigotine transdermal ("TDS") patch. The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Over the past 90 days, the Company has been focused on the optimization of its Rotigotine... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) ( OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to report that it has signed a non-binding Letter of Intent ("LOI") to identify and assess potential business synergies for manufacturing, import/export, distribution and product development with a US-based thin film manufacturing firm (the "Firm"). The Firm operates a state-of-the art US-based FDA-certified pharma production... Read More

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds. Each compound was designed to provide specific alterations in their respective biopharmaceutical properties. The library of compounds can be selected to target (personalize) the treatment of neuropsychiatric, and... Read More

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (" XPhyto " or the " Company ") is pleased to announce that further to its news releases of July 22, 2022, August 2, 2022 and August 30, 2022, it has closed the final tranche of its private placement in the amount of 2,190,000 units of the Company (the " Units ") at a price of $0.36 per Unit for total gross proceeds of $788,400. Each Unit consists of one common share... Read More

XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) (" XPhyto " or the " Company ") is pleased to announce that further to its news releases of July 22, 2022, and August 2, 2022, it has closed the second tranche of its private placement in the amount of 5,000,000 units of the Company (the " Units ") at a price of $0.36 per Unit for total gross proceeds of $1,800,000. Each Unit consists of one common share of the Company... Read More

XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder ("OUD") and pain have been recently associated with numerous serious oral health problems requiring medical... Read More

XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder ("OUD") and pain have been recently associated with numerous serious oral health problems requiring medical... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to report that Dr. Florian A. Sahr has joined its European operations as Head of Project Management. Dr. Sahr is a German-born and internationally trained leader in drug formulation, technology transfer and new-product manufacturing. Dr. Sahr has a strong track record of drug development, including transdermal ("TDS") and oral... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product development report on its Rotigotine transdermal ("TDS") patch, including results of its recent human cadaver skin permeation study, first announced April 4, 2022. The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH... Read More

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Sublingual oral dissolvable film ("ODF") biosensor development pipeline. The Company's oral dissolvable products are based on the ODF platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), which incorporates proprietary... Read More

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Rotigotine transdermal ("TDS") patch. The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"). Rotigotine is a non-ergoline dopamine agonist approved for the treatment of... Read More

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that further to its news release of March 25, 2022, it has closed the first tranche of its private placement. The Company issued 1,250,000 common shares at $1.00 per share for total gross proceeds of $1,250,000. The Company paid $100,000 and issued 100,000 share purchase warrants in finder's fees with respect to the... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on its wholly owned subsidiary XPhyto Laboratories Inc. ("XPhyto Labs"). XPhyto Labs' psychedelic medicine programs based in Edmonton, Canada, are focused on a multi-pronged approach to psychedelic medicine including GMP drug synthesis, proprietary drug delivery systems, novel psychedelic analogue... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to report on its three business divisions as part of its product development, commercialization, and revenue growth strategy: I) Vektor Pharma, II) 3a-diagnostics, and III) XPhyto Laboratories. Vektor Pharma Vektor Pharma TF GmbH ("Vektor Pharma"), based in Uttenweiler, Baden-Württemberg, Germany, is a 100% wholly owned... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the integration of 3a-diagnostics GmbH ("3a") into XPhyto's German operations. The acquisition of 3a, announced December 6, 2021, is a primary driver of XPhyto's recent management activities in Germany. The Company has been working diligently to expedite the launch of its COVID-ID lab test system into... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Drahoslav Zdarek as the Company's Head of Sales, Europe. Mr. Zdarek will focus on building out distribution, sales and marketing of the Company's products, with high priority on the commercialization of Covid-ID Lab, the Company's German CE Mark approved rapid RT-PCR test registered within... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products including for the detection of COVID-19. Director of Business Development Mr. Roland Spleiss has joined as the Director of Business Development. Mr. Spleiss is a seasoned commercial... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending human pilot study, the Company is pleased to announce that its European human CBD bioavailability study will commence in January 2022. Prof. Dr. Beckert said,... Read More

The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technology The acquisition of 3a, a German-based rapid point-of-care diagnostics firm adds IP and a deeply experienced scientific expertise to XPhyto Gains technical and business synergies Secures XPhyto a near-term infectious disease biosensor portfolio and related Intellectual Property XPhyto... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) (the " Company " or " XPhyto ") announces that it has issued an aggregate of 1,850,000 stock options (the " Options ") in accordance with the Company's stock option plan (the " Option Plan ") at an exercise price of $1.25 per share. 1,750,000 Options will expire on November 29, 2026 and 100,000 Options will expire on November 29, 2023. The Options were granted to... Read More

XPhyto Therapeutics Corp. (" XPhyto " or the " Company ") (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce that further to its news release dated November 3, 2021, it has now closed its $1.00 common share non-brokered private placement (the " Equity Offering "), as well as its previously announced non-brokered convertible debenture unit offering (the " Debenture Offering "). The Equity Offering resulted in the... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Joseph Meagher as Chief Financial Officer of the Company. Mr. Meagher is a Chartered Professional Accountant (CPA, CA) and a Chartered Director (C.Dir.). He is currently the CFO of Defence Therapeutics Corp (CSE:DTC), a publicly-traded biotechnology company engineering next generation... Read More

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Prof. Dr. Thomas Beckert as the managing director of XP Diagnostics GmbH, a 100% owned subsidiary of XPhyto. With the next phase of growth and development, Prof. Dr. Thomas Beckert will be appointed to the position of managing director of XP Diagnostics GmbH to run XPhyto's operations in Germany... Read More

Rotigotine transdermal skin patch optimization and pivotal study planning underway Rotigotine patch manufacturing, sales and marketing in preparation Cannabinoid oral dissolvable film (ODF) programs advanced, CBD ODF ready for pilot study Prioritization of additional near-term drug formulation programs underway XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce... Read More

XPhyto Therapeutics Corp. ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto" or the" Company ") announces it has entered into extensions to investor relations consulting agreements with each of Knox Communications Inc. (" KCI ") and M. Davis & Associates Capital Inc. (" Davis "), to carry out marketing and investor communications activities for the Company. KCI's engagement is extended for a 12 month period beginning on October... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the successful market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab. The pilot project at the test centers in Berlin has successfully optimized the operational procedures and protocols for the rapid, efficient and reliable use of COVID-ID Lab. This technical and operational knowledge is a critical... Read More

Biosensor test dissolves on the tongue and turns bitter indicating the presence of oral inflammation after five minutes Easy and simple at-home self-checks improve oral health and indicate inflammation early on Test successfully registered with the German authorities and is ready for partnering with wholesale distribution partners and market launch The global Biosensor market is expected to cross USD 38.7 billion by 2027 at... Read More

First saliva activated biosensor molecules identified to diagnose COVID-19 infection using XPhyto's oral dissolvable delivery platform Biosensor candidates are ready for optimization and performance assessment Development of biosensor screening test would expand XPhyto's diagnostic product pipeline for COVID‑19 and additional infectious diseases Biosensor candidates present an innovative low-cost diagnostic alternative... Read More

The acquisition creates significant commercial development and manufacturing opportunities for XPhyto as well as cost synergies and improved margins on its diagnostic products. The acquisition secures XPhyto an experienced research and development team with a pipeline of ready-to-launch biosensor products. The acquisition facilitates XPhyto's aggressive expansion into the point-of-care biosensor market which is growing at 8%... Read More

VANCOUVER, BC / ACCESSWIRE / July 2, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") announces that pursuant to its advertising agreement with AGORA Internet Relations Corp. ("AGORA") dated December 1, 2020 (the "Advertising Agreement"), the Company issued 7.957 common shares on June 17, 2021 to AGORA in consideration for advertising services provided to the Company during the... Read More

XPhyto signs master supply agreement with operator of 10 COVID-19 test centers The test will be offered to customers as a rapid PCR test with sample processing on site Commercial operations expected to commence upon delivery of kits XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has signed a master supply agreement with Beovita GmbH & Co. KG and... Read More

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands... Read More

Research and development lab set up, preliminary mescaline synthesis complete Modified synthesis process developed, mescaline batches manufactured Development of analytical methods and validation, GMP standard operating procedures and manufacturing scale-up underway XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its GMP mescaline synthesis program is on... Read More

Rapid 25-minute point-of-care COVID-19 PCR test available for purchase in Germany commencing May 25, 2021 Volume based pricing competitive with other COVID-19 PCR test products on the market Initial manufacturing capacity secured, additional capacity to increase based on demand XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its distribution, storage and... Read More

Rotigotine transdermal human pilot study successfully completed; program advancing to pivotal study Land purchased for construction of commercial drug manufacturing facility in Germany XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its 2021 drug formulation programs are advancing on schedule and continue to expand in scope. XPhyto is a bioscience accelerator... Read More

Pilot project includes point-of-care sample collection, PCR processing and final testing of workflow logistics Project is in cooperation with a German pharmacy currently running a COVID-19 test center Rapid results with high accuracy - 20-minute PCR run plus 5-minute detection process XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) ( FSE:4XT) ("XPhyto" or the "Company") is pleased to announce it has commenced a pilot... Read More

XPhyto delivered 2,000 of its 25-minute PCR tests to Israeli distributor for clinical evaluation and regulatory approval Potential customers include government institutions, private healthcare providers and neighboring countries XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has delivered 2,000 of its rapid 25-minute PCR tests ("Covid-ID Lab") to an... Read More

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") with an established German pharmaceutical wholesaler and service provider (the "Distributor") for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. The Agreement secures XPhyto a full-service distribution partner for its... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the Head of Corporate Development at XP Diagnostics GmbH ("XP Diagnostics"), a wholly owned German subsidiary of the Company. With European CE-IVD approval announced March 18, 2021,... Read More

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to... Read More

CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2 Rapid results with ease of use - single 20-minute PCR cycle plus 5-minute detection process High sensitivity - 104.73 c/PCR limit of detection with 95% confidence interval High specificity - zero cross-reactivity on 19x respiratory infectious disease panel High robustness - no impact on results from minor changes in process parameters 100%... Read More

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce successful EN ISO 13485 certification for the rapid point-of-care, SARS-CoV-2 RT-PCR Test System ("Covid-ID Lab"). This standardization and quality assurance certification provides authorization for distribution of Covid-ID Lab... Read More

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) ("XPhyto" or the "Company"), is pleased to announce that the Company has completed a corporate rebranding and launched a new website which can be viewed at www.xphyto.com . The rebranding decision reflects the Company's commitment to operational achievement in 2021 as a number of product development programs advance from the laboratory to the clinic. As a... Read More

XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Company "), is pleased to announce that it has placed the first order for its rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab") from its exclusive diagnostic development partner, 3a-diagnostics GmbH ("3a"). The first order of Covid-ID Lab is for 9,600 individual tests, which are packaged in 200 kits of 48 tests... Read More

XPhyto Therapeutics Corp . ( CSE:XPHY / OTCQB:XPHYF / FSE:4XT ) (" XPhyto " or the " Company "), is pleased to announce that the Company has expedited the formation of an experienced commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab"). Covid-ID Lab was developed by XPhyto's exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"). XPhyto expects 3a to... Read More

XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Corporation ") is providing the following comments regarding a claim made against Vektor Pharma TF GMBH ("Vektor"), one of the Corporation's German subsidiaries. Vektor is subject to a declaratory action made by a former client and current competitor (the "Claimant") in relation to alleged breach of the terms of a development agreement... Read More

XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Company "), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce that all actions and procedures required for its European regulatory application for the rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR Test System ("Covid-ID Lab") have been completed. 3a expects ISO 13485 approval as... Read More

XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) (" XPhyto " or the " Company ") is pleased to announce that XPhyto Laboratories Inc., its wholly owned Alberta subsidiary, has added mescaline production to its psychedelic medicine programs. Further to the Company's press release dated February 3, 2021, the capacity under contract with Applied Pharmaceutical Innovation will focus on the synthesis of... Read More

XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT) (" XPhyto " or the " Company ") is pleased to announce that XPhyto Laboratories Inc. ("XPhyto Labs"), its wholly owned Alberta subsidiary, has signed an agreement (the "Agreement") with Applied Pharmaceutical Innovation ("Applied") for the synthesis of pharmaceutical grade psychedelic compounds and the parallel development of the standard operating procedures... Read More

Construction of commercial drug manufacturing facility in Germany Four clinical studies in neurological indications in 2021 Development of oral biosensor and contract development & manufacturing Psychedelic transdermal and sublingual drug formulation development XPhyto Therapeutics Corp . ( CSE:XPHY) (OTCQB:XPHYF) (FSE:4XT ) (" XPhyto " or the " Company ") is pleased to announce its drug formulation and delivery business... Read More